Question

Difficulty: HardNormal Pregnancy and Prenatal Care

A 29-year-old primigravida presents to the obstetrics clinic to establish prenatal care. According to a recent dating ultrasound, she is at 9 weeks gestation. She has no significant past medical history and currently takes a daily prenatal vitamin. Her blood pressure is 112/68 mm Hg, heart rate is 82/min, and body mass index is 23 kg/m 2^2. Physical examination is unremarkable. The patient is eager to understand the upcoming milestones in her pregnancy and asks the physician to explain the precise timeline of routine testing she will undergo over the next several months.

Arrange the following routine prenatal screening tests and evaluations in the chronological order they should be offered or performed during this patient's uncomplicated pregnancy.

  1. 1Measurement of fetal nuchal translucency and maternal serum pregnancy-associated plasma protein A (PAPP-A)
  2. 2Maternal serum alpha-fetoprotein (MSAFP) measurement for neural tube defect risk assessment
  3. 3Comprehensive transabdominal ultrasound for fetal anatomic survey
  4. 4Screening for gestational diabetes mellitus using a 50-g oral glucose challenge test
  5. 5Rectovaginal swab culture to assess for Group B Streptococcus colonization

Answer

The correct chronological sequence is: First-trimester combined screening (nuchal translucency and PAPP-A), followed by MSAFP measurement, then the comprehensive fetal anatomic survey, then gestational diabetes screening, and finally Group B Streptococcus rectovaginal culture.
Routine prenatal care follows a highly standardized schedule based on fetal developmental milestones and maternal physiologic adaptations. The first-trimester combined screen (NT + PAPP-A) must be completed within a strict window of 10 to 14 weeks. MSAFP is optimally drawn between 15 and 18 weeks to evaluate for neural tube defects. The comprehensive anatomy ultrasound is then performed between 18 and 22 weeks when fetal structures are large enough to be clearly visualized. Gestational diabetes screening occurs at 24 to 28 weeks, coinciding with the physiologic peak in placental lactogen and resulting insulin resistance. Finally, GBS screening is performed at 36 to 38 weeks, close enough to term to predict intrapartum colonization status accurately.

Step-by-Step Solution

1
Identify the timing for first-trimester aneuploidy screening.
Measurement of nuchal translucency and PAPP-A is performed between 10 0/7 and 13 6/7 weeks gestation.
This is the earliest targeted screening in the provided list, relying on specific ultrasound and serum markers that are only diagnostically valid during this narrow first-trimester window.
2
Identify the timing for early second-trimester serum screening.
Maternal serum alpha-fetoprotein (MSAFP) is optimally measured between 15 0/7 and 18 0/7 weeks gestation.
MSAFP evaluates the risk for open neural tube defects and is typically obtained before the routine anatomy scan is performed.
3
Identify the timing for the routine fetal anatomic survey.
A comprehensive transabdominal ultrasound is performed between 18 0/7 and 22 6/7 weeks gestation.
This gestational age provides the optimal balance of fetal organ development and amniotic fluid volume to visualize and assess structural anatomy.
4
Identify the timing for gestational diabetes screening.
A 50-g oral glucose challenge test is performed between 24 0/7 and 28 0/7 weeks gestation.
Human placental lactogen (hPL) levels peak during the late second trimester, creating maximal physiologic insulin resistance, which unmasks gestational diabetes.
5
Identify the timing for Group B Streptococcus (GBS) screening.
A rectovaginal swab culture is obtained between 36 0/7 and 37 6/7 weeks gestation.
Screening is performed in the late third trimester so that culture results accurately reflect the maternal colonization status at the actual time of delivery.

Key Concept

Chronological timeline of routine prenatal screening and maternal physiologic adaptations
Rate this question